Survival Curve from Scientific Research

Kaplan–Meier curves displaying PFS probability of patients with HR + /HER2 − MBCs treated in combination with CDK4/6 inhibition (hazard ratio, 1.5; 95% CI, 1.2–1.8; P = 2.4 × 10 −4 for APOBEC3-dominant versus Others and hazard ratio, 1.8; 95% CI, 1.4–2.2; P = 6.4 × 10 −7 for HRD-dominant versus Others). Patients were categorized according to the dominant mutational signatures of the biopsy obtained before start of treatment. Groups were compared using log rank test.

DOI